Roivant Sciences Stock (NASDAQ:ROIV)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$11.31

52W Range

$8.61 - $13.05

50D Avg

$11.72

200D Avg

$11.20

Market Cap

$8.36B

Avg Vol (3M)

$6.07M

Beta

1.24

Div Yield

-

ROIV Company Profile


Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

GB

Employees

908

IPO Date

Dec 08, 2020

Website

ROIV Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceMar 24Mar 23
Product$75.06M$28.01M

Fiscal year ends in Mar 24 | Currency in USD

ROIV Financial Summary


Mar 24Mar 23Mar 22
Revenue$124.80M$61.28M$55.29M
Operating Income$4.24B$-1.08B$-1.21B
Net Income$4.35B$-1.23B$-924.12M
EBITDA$-996.51M$-1.11B$-1.50B
Basic EPS$5.55$-1.73$-1.38
Diluted EPS$5.23$-1.73$-1.38

Fiscal year ends in Mar 24 | Currency in USD

Latest Earnings Call Transcripts


Q2 24Nov 12, 24 | 2:41 PM
Q1 25Aug 09, 24 | 12:03 PM
Q4 23May 30, 24 | 12:23 PM

Peer Comparison


TickerCompany
PLRXPliant Therapeutics, Inc.
AKROAkero Therapeutics, Inc.
CGEMCullinan Oncology, Inc.
RVMDRevolution Medicines, Inc. Warrant
VRDNViridian Therapeutics, Inc.
APLSApellis Pharmaceuticals, Inc.
BPMCBlueprint Medicines Corporation
DAWNDay One Biopharmaceuticals, Inc.
PHATPhathom Pharmaceuticals, Inc.
BGNEBeiGene, Ltd.
SNDXSyndax Pharmaceuticals, Inc.
RXDXPrometheus Biosciences, Inc.
INZYInozyme Pharma, Inc.
ASNDAscendis Pharma A/S
KRYSKrystal Biotech, Inc.
LYRALyra Therapeutics, Inc.